{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nguyen HP"],"funding":["Ministry of Education","Bộ Giáo dục và Ðào tạo","Ministry of Science and ICT, South Korea"],"pagination":["22108-22118"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9364358"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(34)"],"pubmed_abstract":["Multiple myeloma is a deadly cancer that is a complex and multifactorial disease. In the present study, 12 belinostat derivatives (four resynthesized and eight new), HDAC inhibitors, were resynthesized <i>via</i> either Knoevenagel condensation, or Wittig reaction, or Heck reaction. Then an evaluation of the antiproliferative activities against myeloma cells MOPC-315 was carried out. Amongst them, compound 7f was the most bioactive compound with an IC<sub>50</sub> of 0.090 ± 0.016 μM, being 3.5-fold more potent than the reference belinostat (IC<sub>50</sub> = 0.318 ± 0.049 μM). Furthermore, we also confirmed the inhibitory activity of 7f in a cellular model. Additionally, we found that the inhibitory activity of 7f against histone deacetylase 6 catalytic activity (HDAC6) is more potent tha"],"journal":["RSC advances"],"pubmed_title":["Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies."],"pmcid":["PMC9364358"],"funding_grant_id":["2018R1A6A1A03025523","B2019-TCT-37 (TCT-05)","2020R1A2B5B02002377","2019M3E5D1A02069623"],"pubmed_authors":["Nguyen CQ","Tuan NT","Van Ky N","Hoa TP","Nguyen HP","Le Dang Q","Hue BTB","Quoc Chau Thanh N","Nhu Thao H","Pham MQ","Duy Binh T","Tran Q","Yang SG"],"additional_accession":[]},"is_claimable":false,"name":"Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies.","description":"Multiple myeloma is a deadly cancer that is a complex and multifactorial disease. In the present study, 12 belinostat derivatives (four resynthesized and eight new), HDAC inhibitors, were resynthesized <i>via</i> either Knoevenagel condensation, or Wittig reaction, or Heck reaction. Then an evaluation of the antiproliferative activities against myeloma cells MOPC-315 was carried out. Amongst them, compound 7f was the most bioactive compound with an IC<sub>50</sub> of 0.090 ± 0.016 μM, being 3.5-fold more potent than the reference belinostat (IC<sub>50</sub> = 0.318 ± 0.049 μM). Furthermore, we also confirmed the inhibitory activity of 7f in a cellular model. Additionally, we found that the inhibitory activity of 7f against histone deacetylase 6 catalytic activity (HDAC6) is more potent tha","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-09T19:35:05.067Z","creation":"2025-04-21T14:47:28.683Z"},"accession":"S-EPMC9364358","cross_references":{"pubmed":["36043105"],"doi":["10.1039/d2ra01969h"]}}